

### Welcome and Opening

9:00-9:15	Peking University	<b>Jie Wang</b> , Vice President of Peking University
9:15-9:30	Boehringer Ingelheim	<b>Clive Wood</b> , Head, Discovery Research, BI
9:30-10:00	Signing Ceremony	
10:00-10:10	Institute of Molecular Medicine	<b>Rui-Ping Xiao</b> , Director, Institute of Molecular Medicine
10:10-10:20	College of Chemistry and Molecular Engineering	<b>Yiqin Gao</b> , Dean, College of Chemistry and Molecular Engineering
10:20-10:30	School of Life Sciences	<b>Chenjian Li</b> , Vice Dean, School of Life Sciences; Vice Provost, PKU

### Coffee break 15 min

10:45-11:00	<b>Jonathon Sedgewick</b> , <i>Global Head, Cancer Immunology and Immune Modulation, BI</i>	Cancer Immunology and Immune Modulation
11:00-11:20	<b>Zemin Zhang</b> , <i>Principle Investigator, School of Life Sciences, PKU</i>	Characteristics of tumor infiltrating lymphocytes revealed by single cell sequencing
11:20-11:40	<b>Jiazhi Hu</b> , <i>Principle Investigator, School of Life Sciences, PKU</i>	Revealing antibody repertoires and evaluating off-target activities of engineered nucleases by next-generation sequencing
11:40-12:00	<b>Zhengfan Jiang</b> , <i>Principle Investigator, School of Life Sciences, PKU</i>	Innate immunity and related cell signaling

### 12:00-13:00 Lunch

13:00-13:15	<b>Henri Doods</b> , <i>Global Head, Research Beyond Borders, BI</i>	A global BI approach to capture external innovation
13:15-13:35	<b>Hongkui Deng</b> , <i>Principle Investigator, School of Life Sciences, PKU</i>	Derivation of stem cells with totipotent-like developmental potentials
13:35-13:55	<b>Demin Zhou</b> , <i>Principle Investigator and Dean, School of Pharmaceutical Sciences, PKU</i>	A general methodology for conversion of life-threatening viruses into live virus vaccine
14:00-14:15	<b>Eric Haaksma</b> , <i>Site Head, Research Germany, BI</i>	Innovation at BI NCE Discovery
14:15-14:35	<b>Lei Chen</b> , <i>Principle Investigator, Institute of Molecular Medicine, PKU</i>	Towards the mechanism of ATP-sensitive potassium channel ( $K_{ATP}$ )
14:35-14:55	<b>Ning Gao</b> , <i>Principle Investigator, School of Life Sciences, PKU</i>	When mRNA goes bad: Translation termination without a stop codon
14:55-15:15	<b>Peng Zou</b> , <i>Principle Investigator, College of Chemistry and Molecular Engineering, PKU</i>	Lighting up the Brain with a Flare: a Hybrid Voltage Indicator for Optical Mapping of Neural Activity

### Coffee break 15 min

15:30-15:45	<b>Michael Mark</b> , <i>Global Head, CardioMetabolic Discovery Research, BI</i>	CardioMetabolic Diseases Research in Boehringer Ingelheim- Current Status and future outlook
15:45-16:05	<b>Rui-Ping Xiao</b> , <i>Principle Investigator, Institute of Molecular Medicine, PKU</i>	Glucose-inducible Myokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis
16:05-16:25	<b>Xiao-Wei Chen</b> , <i>Principle Investigator, Institute of Molecular Medicine, PKU</i>	Quantitative Control of Lipid Transport by the CMRD Gene SAR1B
16:25-16:40	<b>Norbert Kraut</b> , <i>Head, Oncology, BI</i>	Cancer Research at Boehringer Ingelheim- Portfolio and partnerships
16:40-17:00	<b>Chengqi Yi</b> , <i>Principle Investigator, School of Life Sciences, PKU</i>	Sequencing RNA Modifications in the Mammalian Transcriptome
17:00-17:20	<b>Xiong Ji</b> , <i>Principle Investigator, School of Life Sciences, PKU</i>	Gene Control and Chromosome Structure

### Closing Remarks

17:20-17:25	Boehringer Ingelheim	<b>Henri Doods</b> , Global Head, Research Beyond Borders, BI
17:25-17:30	Peking University	<b>Rui-Ping Xiao</b> , Director, Institute of Molecular Medicine, PKU

## Speaker's Biography (in the order of appearance)



### **Prof. Jie Wang, Ph.D of Science**

*Vice President, Peking University*

Prof. Jie Wang was born in 1956 and received Bachelor degree of Science at department of Mathematics in Peking University. He continued his education within the same department and got his Master degree of Science in 1985, and became a lecturer since then. In 1991, he received his Ph.D degree of Science at Peking University. Before becoming into a full professor at Peking University in 1995, he spent 2 years at University of Western in Australia. He was in the role of Executive Vice- Dean of School of Mathematical Sciences at Peking University from 1995 to 1998. In year 1998 to 2000, he served as Minister of Organization of CCP Committee at Peking University. Since May, 2013 he is Vice President at Peking

University



### **Clive R. Wood, Ph.D**

*Corporate Senior Vice President and global head of Discovery Research, Boehringer Ingelheim*

Before joining BI in April 2014, Clive was responsible for biologics research, process development and clinical manufacturing at Bayer HealthCare's sites in Germany and the USA (2009-2014). Key contributions include the late-stage development of Kovaltry® (US launch 2016) and other hemophilia programs, early-stage discovery and development of antibody-drug conjugates including anetumab ravtansine in oncology, and building an integrated antibody discovery and protein engineering capability.

Previously he served as CSO, EVP at Dyax Corp (2003-2009) and Genetics Institute, Inc./Wyeth Research (1986-2003) in Cambridge, Massachusetts. His work focused on protein therapeutics in inflammation and oncology, hematopoiesis and cytokine biology (Neumega®, rec. human Interleukin-11, US launch 1997), and the discovery of the ligands of PD-1 and their inhibitory action on T-cell activation.

As a scientist and graduate student at Celltech Ltd., UK, he contributed to early work on the recombinant expression of monoclonal antibodies and is an inventor on the 'Boss patent' (1982-1985).

His educational contributions include serving as Adjunct Professor, Dept. of Pharmacology, Boston University School of Medicine; founding a joint graduate training program between Genetics Institute/Wyeth Research and Boston University; organizing a lecture series for MD/PhD



### **Rui-Ping Xiao, Ph.D**

*Chair Professor and Director, Institute of Molecular of Medicine, Peking University*

Dr. Rui-Ping Xiao is the Director of the Institute of Molecular of Medicine at Peking University and the Peking University Chair Professor. Dr. Xiao's research has been focused on cardiovascular and metabolic diseases, with a major emphasis on a translational approach to take bench discoveries into clinically relevant situations. Ongoing research directions include signaling pathways involved in metabolic syndrome and associated cardiovascular complications. Currently, Dr. Xiao serves as a Council Member of the International Society of Heart Research and an Associate Editor of the New England Journal of

Medicine and an Editorial Board Member of multiple international top journals.



### **Yiqin Gao, Ph.D**

*Professor and Dean, College of Chemistry and Molecular Engineering, Peking University*

Prof. Yiqin Gao got his Bachelor degree in Chemistry at Sichuan University. He then joined Dr. Dalin Yang's group at Institute of Chemistry, Chinese Academy of Sciences and got his Master degree in Chemistry in 1996. He obtained his Ph.D degree in Chemistry at California Institute of Technology in 2001 in Prof. Rudolph A. Marcus' group in 2001. Afterwards, he continued his postdoc training at Prof. Marcus' lab and followed Prof. Martin Karplus at Harvard for postdoc in 2002-2004 before assuming the assistant professor position at Texas A&M University. He returned to China in 2010 as Changjiang Professor and the Director of Institute of Theoretical and Computational Chemistry in College of Chemistry and Molecular

Engineering. Since 2013, he is the principle investigator at Biodynamic Imaging Center. He is currently the Dean of College of Chemistry and Molecular Engineering at Peking University and Visiting Professor at Hong Kong University of Science and Technology.

**Chenjian Li, Ph.D**

*Vice Provost, Peking University; Professor, and Vice Dean, School of Life Sciences*

Dr. Li got his Ph.D. from Purdue University. Before joining PKU, Dr. Li was Alex and Shirley Aidekman Endowed Chair of Neurology, Laboratory of Molecular Genetics and Neurobiology, Dept. Neurology and Friedman Brain Institute, Mount Sinai School of Medicine, NYU.

The Li Laboratory is dedicated to the understanding of how the nervous system works under normal physiological conditions, and how diseases develop under pathological conditions. Currently, they focus on the neurodegenerative diseases such as Parkinson's disease, Huntington's disease and Alzheimer's disease.

They use a wide range of investigative tools including molecular biology, genetics, electrophysiology, biochemistry, and behavioral science. They also use a variety of research organisms including cell culture, Drosophila, transgenic mouse and rat models.

The Li Laboratory is a leading group for inventing genetic methods in transgenic mouse and rats, and has used these methods to establish some of the animal models that are most commonly used by academic labs and pharmaceutical industry in neurodegeneration field. These animal models are powerful tools for mechanistic studies as well as drug discoveries. They are also developing transgenic method for non-human primates, Rhesus monkey as the next generation tools.

**Jonathon Sedgwick, Ph.D**

*Global Head, Cancer Immunology and Immune Modulation*

Jonathon Sedgwick, B.Sc. (Hons) Ph.D. born Perth Australia, is an Immunologist, educated at the University of Western Australia with post-doctoral education at the University of Oxford UK with Don Mason, Neil Barclay and Alan Williams. His subsequent career included ten years in academic research at the University of Wurzburg Germany, and the Centenary Institute of Cancer Medicine, Sydney Australia, six years as Group Director, Immunology, at the DNAX Research Institute, Schering Plough/Merck's biotech arm in Palo Alto,

California, and 11 years with Eli Lilly and Company where he held a number of roles including Chief Scientific Officer, Cancer Inflammation Research; Managing Director and Chief Scientific Officer of Lilly's Singapore Research Center, and Chief Scientific Officer, Autoimmunity Discovery Research and Distinguished Research Fellow, Biotechnology and Autoimmunity.

In November 2015 Jonathon joined the German Biopharmaceutical Company Boehringer Ingelheim as Vice President and Global Head Immune Modulation and Biotherapeutics Discovery Research. In December 2016 Jonathon was appointed to the new role of Vice President and Global Head Cancer Immunology and Immune Modulation. In this role he is responsible for the development of the Immuno-oncology discovery and early clinical portfolio, and for immune-modulation research globally contributing immunology target concepts and discovery portfolio programs across all therapy areas.

Amongst his key contributions to the immunology field was the discovery with colleagues at DNAX of the dominant biological role of the interleukin-23 cytokine in autoimmune inflammation, and through this identifying the IL-17-producing T cell subset, Th17. This work was fundamental in reorienting the autoimmune therapy field towards a focus on therapeutics in the IL-23/Th17/IL-17 axis, with drugs directed to these pathway components now launched (IL-17A inhibitors including the mAb ixekizumab from Eli Lilly) and others including IL-23p19 inhibitors in phase 2 and 3 clinical testing across multiple companies. Jonathon has authored or co-authored 120 peer-reviewed, review articles and book chapters.

**Zemin Zhang, Ph.D**

*Professor and Principle Investigator, Biodynamic and Optical Imaging Center and School of Life Sciences, Peking University*

Dr. Zemin Zhang is a Professor of Peking University and a principal investigator at BIOPIC, the Center for Life Sciences of Peking and Tsinghua Universities, and Beijing Advanced Innovation Center for Genomics. Dr. Zhang obtained his BS from Nankai University, PhD from Penn State University and postdoctoral trainings at UCSF. Dr. Zhang spent 16 plus years at Genentech/Roche, leading the cancer genomics and bioinformatics group to discover anticancer targets and biomarkers using cutting technologies such as

machine learning and high throughput sequencing. He has pioneered multiple research directions in computational cancer biology and cancer genomics including the first ever whole genome tumor sequencing. He is also an inventor for 60 issued US patents, and has directly contributed to the initial finding of the molecular targets of multiple cancer therapeutic agents in clinical trials. His lab



currently focuses on understanding the interplay between immune and cancer cells using both large-scale cancer genomics data and the cutting edge single cell sequencing technologies. He is on the editorial boards for journals including Cell Systems, Genome Medicine, and Cancer Informatics. He is a CUSBEA Scholar, a recipient of the 1000 Talents program, and is also a Cheung Kong Scholar.



**Jiazhi Hu, Ph.D**

*Assistant Professor and Principle Investigator, School of Life Sciences, Peking University*

Dr. Jiazhi Hu received his Bachelor degree in 2006 and Ph.D in Biochemistry and Molecular Biology in 2012 from School of Life Sciences at Peking University. He then worked as Research Fellow at Dr. Frederick Alt's lab until 2016 in Boston Children's Hospital, USA. He came back to China and took the position of assistant professor at School of Life Sciences at Peking University. His research interests include: 1) Elucidate the mechanism of genome stability during lymphocyte development, and investigate into the roles of RAG, AID, transcription, and DNA replication in tumorigenesis; 2) Identify genomic mutations in the cancer cells involving in metastasis by changing the 3-D genome structures; 3) Develop new assays for antibody and T cell receptor repertoire sequencing and screen for new antigen receptors for cancer immunotherapy.



**Zhengfan Jiang, Ph.D**

*Professor and Principle Investigator, School of Life Sciences, Peking University*

Dr. Zhengfan Jiang received his Bachelor degree in Biology in 1991 and Master degree in Biology in 1994, from Lanzhou University. He got his Ph.D degree from School of Life Sciences at Peking University in 1997. In 1997-1999, he worked as postdoc at School of Life Sciences at Peking University, and moved to Lerner Research Institute thereafter and joined Dr. Xiaoxia Li's Lab as research associate from 1999-2003. Then he worked in Dr. Bruce Beutler's Lab at The Scripps Research Institute, USA as Research Associate until 2006. Then, he returned to China and took the professor position at School of Life Sciences at Peking University. His research interest is focused on innate immunity and related cell signaling. He is Changjiang Scholar Professor and the holder of Distinguished Youth Scholar Award.



**Henri Doods, Ph.D**

*Global Head, Research Beyond Borders, Boehringer Ingelheim*

Henri Doods received his PhD in Pharmacology at the University of Amsterdam. He joined Boehringer Ingelheim in 1987 and covered different positions within cardiovascular, pain, obesity, central nervous system and respiratory research. Currently, he heads the Global Department Research Beyond Borders with the responsibility to capture emerging science/new indications and novel technologies/modalities. He is (co) author of more than 135 publications and was involved in progressing > 15 compounds into development.



**Hongkui Deng, Ph.D**

*Professor of Cell Biology, Principal Investigator of School of Life Sciences, Peking University, Director of Stem Cell Research Center*

Hongkui Deng is a Professor of Cell Biology and Principal Investigator of Center for Life Sciences at Peking University. He is also Director of Peking University Stem Cell Research Center. Dr. Deng's laboratory works on cellular reprogramming and generation of functional human cells from pluripotent stem cells. Dr. Deng has published over 100 research articles, reviews and position papers, and made several seminal contributions to the stem cell field. He has served as Board Director of International Society for Stem Cell Research, and as an Editorial Board Member of Cell and Cell Stem Cell.

**Demin Zhou, Ph.D**

*Professor and Dean, School of Pharmaceutical Sciences, Peking University*

Prof. Zhou is the dean of School of Pharmaceutical Sciences at Peking University. He also serves as the Director of the State Key Laboratory of Natural and Biomimetic Drugs of China. He got his bachelor degree from Beijing Medical University in 1990 and joint Ph.D. degree from Beijing Medical University /University of Tsukuba, Japan in 1996. After 3 years teaching in University of Tsukuba of Japan, Dr. Zhou went to USA in 1999 as a postdoctoral for further training in University of California at Berkeley/The Scripps Research Institute under supervision of Prof. Peter G. Schultz. From 2002 he joined the American pharmaceutical industry, starting from Chugai-Roche as a senior scientist and then Immusol Inc. as a group leader and later division head. From the end of 2008, Dr. Zhou was recruited by Peking University as a full professor in China. He is currently a Yangtze River Scholars Distinguished Professor and the Leading Scientist for one of China "973" Major Project. His research area is to develop new chemicals and biotechnologies, based on integration of chemistry and biology, for improvement of the targeting and efficiency of anti-virus and anti-cancer drugs. Dr. Zhou serves on the editorial board for several international journals including J Med Chem, Eur J Med Chem and Inter J Virology & AIDS and is the executive editor of a domestic journal J Chin Pharm Sci.

**Eric Haaksma, Ph.D**


*Site Head, Research Site Germany, Boehringer Ingelheim*

Eric Haaksma studied chemistry at the Free University in Amsterdam, where he obtained his degree in pharmacochemistry in 1986. His PhD studies focused on the topic of theoretical models for activation and inhibition of histamine H<sub>2</sub>-receptors.

Subsequently, he joined the Molecular Modeling group of Boehringer Ingelheim in Biberach as Laboratory Head in 1991. From 1997 till 1999 he was group leader Structural Research in the Dept. of Medicinal Chemistry which comprised the disciplines Molecular Modeling, Molecular Biology, X-ray crystallography

and NMR.

In 2000 he moved to Vienna to build the Department of Medicinal Chemistry, including the disciplines Medicinal Chemistry, Analytics, Structural Research and Drug Discovery Support. From December 2009 till 2015 he held the role of Senior Vice President Research in Vienna. Since October 2015 he holds the position of Head of Research Site Germany.

**Dr. Lei Chen, Ph.D**


*Assistant Professor and Principle Investigator, Institute of Molecular Medicine, Peking University*

Dr. Lei Chen is an investigator in Institute of Molecular Medicine at Peking University. He received a bachelor degree in biology in Tsinghua University in 2005 and received his PhD degree under Jia-Wei Wu and Zhi-Xin Wang's mentorship in Tsinghua University at 2010. He took a postdoc with Eric Gouaux in Vollum Institute, OHSU. His lab is currently working on the gating mechanism of a few ion channels.

**Ning Gao, Ph.D**

*Professor and Principle Investigator, School of Life Sciences, Peking University*

Dr. Ning Gao received bachelor degree in Biochemistry and Molecular Biology in 2000 from School of Life Sciences at Peking. He then moved to USA to pursue his Ph.D with Dr. Joachim Frank and got Ph.D degree in Biomedical Sciences from School of Public Health, State University of New York at Albany in 2006. Afterwards, he worked as Research Affiliate at Wadsworth Center, Albany, New York and Research Associate at Howard Hughes Medical Institutes at Columbia University, New York in 2006-2008. He then worked as Assistant Professor, Tenured Associate Professor and Professor, at School of Life Sciences at Tsinghua University in Beijing. Recently, he joined School of Life Sciences at Peking University. His primary research interest is to study the mechanisms governing various molecular machines inside the cell, using cryo-electron microscopy and three-dimensional reconstruction techniques as major tools. The current effort in the lab is to understand the complex process of ribosome biogenesis in bacterial and yeast cells. In the past several years, Gao lab has focused on functional and structural characterization of various factors involved in the assembly of ribosomal subunits. These data have revealed molecular roles of these factors in the assembly process, and more importantly pinpointed novel regulatory roles of these factors in translation control.



**Peng Zou, Ph.D**

*Assistant Professor and Principle Investigator College of Chemistry and Molecular Engineering, Peking University; Principle Investigator, Synthetic and Functional Biomolecules Center, PKU-IDG/McGovern Institute for Brain Research*

Dr. Peng Zou received his Bachelor degree in Chemistry with double major in Physics in 2007 at Peking University. He received his Ph.D under the mentorship of Dr. Alice Y. Ting's lab at MIT in 2012. He worked as postdoc at Dr. Adam E Cohen's lab at Harvard University in 2013-2015. Since 2015, he returned to China and took Assistant Professor position at College of Chemistry and Molecular Engineering at Peking

University. His research is aiming to invent chemical and physical tools probe neural activities and structure. His team applies these tools to study physical forces, ionic fluxes, and biomolecules that underlie neuronal functions and signaling, all within the context of living cells and with high spatial and temporal resolutions. Examples are fluorescent sensors, engineered enzymes, custom-built microscopes and software etc. Current research projects include: optical detection of action potential waveforms; chemical tools for mapping protein-DNA interactions in neuronal RNA granules; synaptic ribosome profiling.




**Michael Mark, Ph.D**

*Global Head, CardioMetabolic Diseases Research, Boehringer Ingelheim*

Michael Mark PhD is the Vice President and Global Head of CardioMetabolic Diseases Research at Boehringer Ingelheim, Germany. In this role, he is responsible for the research and development of innovative treatments for cardiovascular and metabolic diseases including type 2 diabetes mellitus, obesity, NASH and diabetic microvascular complications like eye diseases as well as kidney diseases. Educated as pharmacist Dr. Mark is holding a Ph.D. degree in Pharmacology from the University of Tuebingen in Germany. Dr. Mark has more than 30 years' experience in the pharmaceutical industry. Early in his career, Dr. Mark contributed to the discovery and development of repaglinide, an approved treatment of type 2

diabetes. He pioneered the discovery of the DPP-4 inhibitor linagliptin (Trajenta) and was instrumental in the initiation of the preclinical work for the SGLT2 inhibitor empagliflozin (Jardiance), both compounds globally launched and marketed. Together with his team he developed a competitive portfolio for cardiometabolic treatment options with various preclinical and several clinical developments projects currently ongoing. Dr. Mark served over 6 years as Project Coordinator for SUMMIT, an Innovative Medicines Initiative (IMI)-sponsored European consortium of 19 academic centers and six major pharmaceutical partners, which aimed and succeeded to identify and characterize novel biomarkers and genetic markers for diabetic complications. Dr. Mark authored many peer-reviewed publications and meeting contributions and also various book chapters. In addition he holds numerous patents.



**Xiao-Wei Chen, Ph.D.**

Principle Investigator, PKU-THU Joint Center for Life Sciences; Institute of Molecular Medicine, Peking University

Dr. Xiao-Wei Chen received his Bachelor degree in Biochemistry and Molecular Biology with double major in Economics from Peking University in 2002. He received his Ph.D degree in Molecular and Integrative Physiology from University of Michigan in 2008.

He worked as Research Fellow in the Laboratory of David Ginsburg HHMI at University of Michigan in 2008-2013, and assumed the position as Research Investigator at Life Sciences Institute at University of Michigan in 2013-2014. He returned back to China and took the Principle Investigator position at Institute

of Molecular Medicine since 2014. His research interest is focused on energy metabolism, diabetes, atherosclerosis, membrane organelle and transport.




**Norbert Kraut, Ph.D, Professor**

*Global Head, Cancer Research, Boehringer Ingelheim*

Prof. Kraut is currently Global Head of Cancer Research at Boehringer Ingelheim located in Vienna, Austria. He received his Diploma in Biology from University of Colorado, Boulder in USA in 1990, and received his Ph.D degree from the European Molecular Biology Laboratories (EMBL) in Heidelberg, Germany in 1994. He joined Fred Hutchinson Cancer Research Center in Seattle USA as postdoc in thereafter, and became into Staff Scientist in 1997. He got habilitation in Physiological Chemistry at University of Ulm, Germany in 2001.

Prof. Kraut joined Boehringer Ingelheim since 1998 as team leader in Genomics Group till 2001, and then assumed the position as

team leader and project leader in the Department of Cardiovascular Research in 2001. Then he moved to Research Site Vienna and took increasing responsibilities. From 2001-2002 he was the Associate Director in the Department of NCE Lead Discovery, Division Oncology. From 2002-2006, he was Department Head and Director of Lead Discovery in Division of Oncology. He was Vice President of Lead Discovery, Division Oncology from 2006-2013. Since 1/2014, he became into Global Head and Vice President, Cancer Research, and Chair of Cancer Research Portfolio Committee at Boehringer Ingelheim. He is also member of Discovery Research Leadership Committee and member of Oncology Therapeutic Area Leadership Committee at Boehringer Ingelheim. Apart from his service at BI, he was lecturer at Faculty of Medicine, at University of Ulm in 2001-2005, and became into Adjunct Professor at Department of Physiological Chemistry since 2005.



***Chengqi Yi, Ph.D***

*Principle Investigator, Synthetic and Functional Biomolecules Center (SFBC), Peking University; Principle Investigator, Peking-Tsinghua Center for Life Sciences;*

Principle Investigator, School of Life Sciences, Peking University

Dr. Chengqi Yi got his Bachelor degree Ph.D in Chemistry from University of Science and Technology of China, and received his Ph.D degree in Chemistry with the mentorship of Prof Chuan He at University of Chicago in 2010. He then worked at postdoc fellow at Prof. Tao Pan's group at University of Chicago in 2010-2011. He came back to Peking University as Principle Investigator since 2012. His research interest is focused on DNA&RNA epigenetics, Chemical Biology, Sequencing Technologies, and Diseases and Biomarkers



***Xiong Ji, Ph.D***

*Principle Investigator, School of Life Sciences Peking University, Peking-Tsinghua Center for Life Sciences*

Dr. Xiong Ji received his Bachelor degree in Biology from Wuhan University in 2008. In 2008-2013, he studied at Wuhan University to pursue his Ph.D and worked as visiting graduate student under mentorship of Dr. Xiang-Dong Fu at UCSD in USA in 2009-2012. He joined Dr. Richard A. Young's group as postdoc at Whitehead Institute for Biomedical Research since 2013. He came back to China and resumed as assistant professor at School of Life Sciences at Peking University in 2016.

His research interest is focused on understanding the fundamental principles of selective gene expression in mammalian cells. We use early embryonic stem cells and cancer cells as our model system, combine genomics, proteomics, bioinformatics, genome editing, imaging and biochemistry techniques. Specific research direction includes: 1) Investigating the molecular mechanisms for chromatin interactions connecting enhancers, promoters and insulators; 2) Understanding the dynamics of chromatin interactions among transcription regulatory elements and how they drive selective gene expression; 3) Identifying development and disease associated functional transcription regulatory elements and their regulation mechanisms.



## Other VIP guests from Boehringer Ingelheim



**Dr. Frank Kalkbrenner**

*Managing Director of the Boehringer Ingelheim Corporate Venture Fund*

Dr. Frank Kalkbrenner is Managing Director of the Boehringer Ingelheim Corporate Venture Fund. Over the last years, he has been involved in several investments of the fund. He serves as board member of STAT Diagnostica in Barcelona, Eyevensys in Paris, Hookipa in Vienna and Acousia Therapeutics in Tübingen. In addition, he is member of the supervisory and the advisory board of Inserm Transfer Initiative a French Seed Investment Fund based in Paris and has an Observer role in the Board of Amal Therapeutics in Geneva.

Frank studied medicine and holds a degree in Pharmacology and Toxicology. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of

Pharmacology of the Freie Universität, Berlin. His academic research focused on gene regulation and signal transduction mediated by ion channels and G proteins.

In 1997 he began his industrial career by joining Schering AG as senior scientist in Experimental Dermatology. Frank joined Boehringer Ingelheim in 1999 and held several positions in the department of Pulmonary Research. In 2005 he took over the responsibility for the Licensing Department. In this function, he was responsible for the licensing activities of the German Boehringer Ingelheim organization as well as for competitive assessment and scientific information systems. In addition, he built up the NBE Research unit at the German Research site in Biberach.

Frank joined the BI Venture fund shortly after its start in 2010.



**Dr. Adrian Carter**

*Corporate Vice President and Global Head of Discovery Research Coordination at Boehringer Ingelheim*

Dr. Adrian Carter is Corporate Vice President and Global Head of Discovery Research Coordination at Boehringer Ingelheim where he is currently responsible for guiding research policy, managing strategic and operational initiatives in Discovery Research, and overseeing competitive intelligence activities in R&D. He originally graduated from the University of Wales in Cardiff with an honours degree in biology, has a Ph.D. in pharmacology from the Department of Medicine at the University of Nottingham, and an executive MBA from the University of Mainz. His career at Boehringer Ingelheim spans more than 31 years including 8 years as head of neuropharmacology where he studied the neurobiology of dopamine, noradrenaline and acetylcholine release as well as the role of NMDA receptors and voltage-dependent sodium channels in

health and disease. Adrian subsequently spent 10 years in business development where he led the negotiations for several large licensing collaborations, co-commercialization deals and patent/royalty settlement agreements. He has been in his current role in Discovery Research since 2011. Adrian currently represents Boehringer Ingelheim on the board of trustees for the Structural Genomics Consortium and the Scientific and Medical Institute in Reutlingen as well as the Innovative Medicines Strategy Priority Working Group of the European Federation of Pharmaceutical Industries and Associations. He is also a member of the steering committee for BioFIT and the Biotech Cluster Rhine-Neckar and the Health Axis Europe executive board.

Check out Adrian's scientific contributions at [https://www.researchgate.net/profile/Adrian\\_Carter2](https://www.researchgate.net/profile/Adrian_Carter2)



**Irene Liu, EMBA, CICPA, ACCA**

*Vice President, Business Development, Boehringer Ingelheim China*

Irene Liu is responsible for BI Greater China (including Hong Kong and Taiwan) investments, mergers and acquisitions, product in-licensing and project cooperation. She has served Sanofi China, Sanofi Australia, GlaxoSmithKline China, Deloitte China, Deloitte Hong Kong. She has more than 15 years of experience in business development in Pharmaceutical field and has successfully completed two acquisition cases and more than 10 product in-licensing and cooperation. She has strong expertise in mergers and acquisitions and a solid background in Finance.



## Program Organizers:



### **Weiyi Zhang, Ph.D**

*Director, External Innovation China, Research Beyond Borders, Boehringer Ingelheim*

Weiyi Zhang is currently the Director, External Innovation China at Boehringer Ingelheim. Weiyi gained her Bachelor degree in Biology at Xiamen University in 2001. She joined international Max-Planck Research School in Chemical Biology in 2003 and studied function of olfactory G-protein coupled receptor in non-olfactory tissues. She obtained her Ph.D in Cell Biology from Ruhr-University Bochum in 2007. Since 2008, Weiyi started Postdoc training in functional study of orphan GPCRs in Central Neural System at both National Institute of Biological Sciences and the University of Hong Kong.

Before joining Boehringer Ingelheim, Weiyi has led a Cell Biology group at BioDuro-PPD in Beijing since 2009, focusing on cell-based assays and integrated early drug discovery programs for various pharmaceutical companies. Then she has led the monoclonal antibody research group at Bio-Rad Laboratory in Shanghai from 2012 to 2013. From 2013 to 2016, Weiyi was the Associate Director at Innovation Center China of Global Drug Discovery at Bayer Healthcare.

Email: [weiyi.zhang@boehringer.com](mailto:weiyi.zhang@boehringer.com)

Tel: +86-10-57653234



### **Xiaojian Zhu, Ph.D**

*Officer, Science and Technology Development Office, and Assistant to the Dean, School of Life Sciences, Peking University*

Dr. Xiaojian Zhu obtained her B.S. degree in Biology in 1992 and Ph.D. degree in Zoology in 1999 from Peking University. She then worked as a lecturer at School of Life Sciences, Peking University, studying large carnivores ecology and conservation, and taught undergraduate courses. In 2014 she switched to the School's Science and Technology Development Office and now is the Assistant to the Dean, working on international collaborations and science and technology developments.

Email: [xjzhu@pku.edu.cn](mailto:xjzhu@pku.edu.cn)

Tel: +86-10-62751857